Infectious Disease · AntimicrobialRegulatory Approvalregulatorymid-term

FDA Grants Approval for Dapsone ANDA218335 by Macleods Pharmaceuticals

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

Macleods Pharmaceuticals10 signalsView page

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/15/2026, 6:05:12 AM

Assessment confidence: 57% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Macleods Pharmaceuticals' ANDA for Dapsone signifies a shift in the competitive landscape for this antimicrobial. This could lead to pricing pressures and necessitate strategic adjustments from existing branded manufacturers to maintain market share. Regulatory context from FDA (FDA AP — DAPSONE (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (5 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of this approval on market dynamics and pricing strategies for Dapsone and similar antimicrobials. The strongest clinical anchor is A Post-marketing Observational Study of Oral Cholera Vaccine (ClinicalTrials.gov), moderate corpus alignment. In Infectious Disease · Antimicrobial, 4 regulatory and 4 competitive items passed relevance filtering for Macleods Pharmaceuticals.

Competitive Pressure

The most relevant competitive pressure comes from FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals. This approval allows Macleods to enter the market with a generic version of Dapsone, potentially increasing competition against existing branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DAPSONE (ORIG) (FDA). Entity match (dapsone); Regulatory pathway relevance (nda). This approval indicates a successful regulatory pathway for generics, which may influence future submissions and approvals in the infectious disease therapeutic area.

Key Risks

Elevated medium regulatory exposure for Macleods Pharmaceuticals could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of a generic version of Dapsone may lead to reduced prices and increased competition, impacting revenue for current branded products in the antimicrobial segment.
Lead sponsor: Bausch & Lomb Incorporated.
Portfolio teams should assess the impact of this approval on market dynamics and pricing strategies for Dapsone and similar antimicrobials.

What Would Change This Assessment

This becomes more urgent if Monitor market entry timelines and pricing strategies of Macleods Pharmaceuticals for Dapsone.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DAPSONE (ORIG)
FDAhigh relevance
Entity match (dapsone); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DAPSONE (ORIG)
FDAhigh relevance
Entity match (dapsone); Regulatory pathway relevance (nda)
FDA document
View source
Rare Disease Drug Approvals
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
FDA’s approval of Veklury (remdesivir) for the treatment of COVID-19—the science of safety and effectiveness
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

A Post-marketing Observational Study of Oral Cholera Vaccine
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Genetic Studies of Chronic Active Epstein-Barr Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
LASER VERSUS CRYSTALLIZED PHENOL IN PILONIDAL SINUS DISEASE
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
A Study Evaluating the Safety and Efficacy of Fixed-Dose Combination for Dry Eye Disease
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
E-cigarette Social Media Marketing and Its Perceptions by Youth
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Post Market Study for VasQ, an External Support Implant for Arteriovenous Fistula
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for primary membranous nephropathy
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for ZERBAXA Supplement by Cubist Pharmaceuticals
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Grants Priority Review for VYVGART Supplement Application
Humanexa Signalsmedium relevance
Moderate corpus alignment
FDA Approves Veklury as First Treatment for COVID-19
Humanexa Signalsmedium relevance
Moderate corpus alignment

RNA polymerase II phosphorylation dynamics: from molecular mechanisms to human disease.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Lactiplantibacillus plantarum (WJL) ameliorates chronic kidney disease by inhibiting fibroblast growth factor 21 adaptive stress response via low protein diet.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Ginger-based formulations for allergic rhinitis disease: a systematic review and meta-analysis of experimental studies in animals and humans.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Macleods Pharmaceuticals
Dapsone
infectious disease market

Commercial impact

medium

The entry of a generic version of Dapsone may lead to reduced prices and increased competition, impacting revenue for current branded products in the antimicrobial segment.

Regulatory impact

medium

This approval indicates a successful regulatory pathway for generics, which may influence future submissions and approvals in the infectious disease therapeutic area.

What to watch

Monitor market entry timelines and pricing strategies of Macleods Pharmaceuticals for Dapsone.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.